PNRI-299 is a selective AP-1 transcription inhibitor (IC50 = 20 μM) and a selective APE/Ref-1 inhibitor; it significantly reduces airway eosinophil infiltration, mucus hypersecretion, edema, and IL-4 levels in a mouse asthma model; it has no effect on NF-κB transcription or thioredoxin.